Skip to main content
Premium Trial:

Request an Annual Quote

It's a Deal

Roche and Genentech have ironed out their differences and announced this morning a friendly deal in which Roche will be buying the 44 percent of Genentech it doesn't already own for $95 a share, reports Agence France-Presse. In a joint statement, Genentech CEO Art Levinson said, "We have had a highly successful partnership with Roche for more than 18 years, and we intend to pursue our shared goal of discovering medications for serious and life-threatening conditions." The deal will total $46.8 billion.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.